Mazindol

A08AA05

Antiobesity

202-203 ° C

10 g · l-1 in DMSO

Risk

36.3 mg · kg -1 ( LD50, rat, oral)

Template: Infobox chemical / molecular formula search available

Mazindol is a tricyclic isoindole derivative and is a drug from the group of stimulants. It is not related to the tricyclic antidepressants.

Pharmacology

Pharmacodynamics

Mazindol inhibits V.A. the resumption of the neurotransmitter norepinephrine.

Pharmacokinetics

Mazindol exerts its maximum effect (Tmax ) after 2 to 4 h Bioavailability is 50%. The half -life is 33-55 h It is excreted via the bile to 25% renal and 75%.

Side effects and interactions

  • Common ( 1% -10 %): angina pectoris.
  • Rare ( < 0.1%): pulmonary hypertension
  • Furthermore: insomnia, dizziness, agitation, confusion, mydriasis, somnolence, apathy, convulsions, coma; Miktionsschwierigkeiten, urinary retention, impotence; Dry mouth, sweating, thirst, chills; Stomach upset, constipation, diarrhea, ileus; rarely palpitations, rash, muscle twitching, tachycardia, hypotension, arrhythmias, shock.

Indications

Mazindol is used for the initial treatment of obesity. Therapeutically useful doses range from 1 to 3 mg / day at breakfast. Meanwhile, this therapeutic principle is obsolete. Since 1990, mazindol in Germany except trade.

Enantiomer CAS registry number PubChem Anatomical Therapeutic Chemical Classification System DrugBank Dangerous Substances Directive (67/548/EEC) Active ingredient Half-life
559580
de